After Strong Sales Results, Is Walgreen a Strong Buy?

On Mar. 5, Walgreen reported financial results that were strong but not strong enough to capture the praise of investors. Is the company a buy, or should investors stay away?

Mar 9, 2014 at 10:00AM

Lake

Source: Wikimedia Commons

On March 5, shares of Walgreen (NASDAQ:WBA) ended the day down nearly 1% as the S&P 500 index stayed roughly even. The reason for the stock's drop was the sales release the business made public covering the month of February as well as results for the fiscal second quarter. In response to this decline, should the Foolish investor consider the company's recent developments too risky to warrant an investment, or is now a good time to buy shares on the cheap?

Walgreen's sales results were actually strong!
Seeing results for Walgreen's monthly performance and its second quarter, investors are probably left wondering why the world's second-largest drugstore chain didn't see a jump in share price as opposed to the fall it experienced. For the month, sales rose 5% to $6 billion from approximately $5.8 billion in the year-ago period. 

Although the business saw sales rise in its front-end operations, the primary source of growth reported was its pharmacy sales. For the month, the company's pharmacy revenue rose nearly 7%, as comparable-store sales soared more than 6%. The only drag on the business was a higher proportion of generic drugs on its shelves, which negatively affected the company's pharmacy revenue by 1.4%.

Picture

Source: Walgreen 

For the quarter, Walgreen's results were still strong. Revenue rose 5.2% from $18.6 billion to $19.6 billion. This slightly beat the $19.5 billion in revenue that Mr. Market anticipated and was mainly attributable to a 4.5% increase in comparable- store sales.

How does Walgreen stack up to the competition?
Over the past four years, Walgreen has done well for itself but hasn't been a superstar. Between 2010 and 2013, the company saw its revenue rise 7% from $67.4 billion to $72.2 billion. In terms of profitability, the business did a little better but not much, with net income rising 17% from approximately $2.1 billion to about $2.4 billion.

The disparity between the company's revenue increase and net income performance was due, in part, to its cost of goods sold falling from 71.9% of sales to 70.8%; meanwhile its income from Alliance Boots (a company it is acquiring) helped prop up its bottom line. These improvements were, however, offset by a rise in the business' selling, general, and administrative expenses, which rose from 23% of sales to 24.3%.

As mediocre as Walgreen's performance may appear, it's better than the way rival Rite Aid (NYSE:RAD) has fared. Between its 2010 and 2013 fiscal years, the company saw its top line fall 1% from $25.7 billion to $25.4 billion. The reason for this drop in sales stems from the company's decision to consolidate operations and focus on returning to profitability rather than trying and grow.

You see, for the past few years, Rite Aid's net income has been in negative territory because of a bloated cost structure and significant impairment charges. In 2010 alone, the company's net loss came out to $506.7 million.

Fortunately, because of its initiatives, the company's cost of goods sold fell from 73.4% of sales to 71.2%, while its selling, general, and administrative expenses only rose slightly; from 25.7% of sales to 26%. This has resulted in the business' net income turning positive in 2013 at $118.1 million, marking the first time since 2006 that the business turned a profit.

While Walgreen has done well compared to Rite Aid, the business has had a hard time keeping up with CVS Caremark (NYSE:CVS). During the same time frame as its peers, CVS has seen its revenue soar 32% from $95.8 billion to $126.8 billion. In an effort to become the Wal-Mart of drugstores, CVS has done all it can to grow sales.

In the long run, this move can grant the business unprecedented buying power, but the downside is that its profits can be depressed for some time. This is made evident in the company's financial results between 2010 and 2012. During this period, CVS recorded a modest 13% increase in net income to approximately $3.9 billion at a time when its revenue rose 29%. In 2013, though, as the business slowed its top-line growth to 3%, its bottom line jumped 19% to approximately $4.6 billion.

Foolish takeaway
Based on the data provided, it looks as though Walgreen had a strong quarter and a strong month in February. Moving forward, it's difficult to tell if the business can maintain this kind of growth, but if it can, it will make for an interesting investment prospect. However, it's important to realize what kind of investment Walgreen is.

Although the business exhibited attractive growth, its long-term performance suggests that it can't hold a candle to CVS. On the other hand, the company's focus on respectable growth, accompanied by nice improvements in profitability, makes it a good play in the drugstore business for those investors looking for a nice, conservative opportunity.

Is Walgreen a company to hold forever?
Because of Walgreen's position as a nice, conservative investment, is it one of The Motley Fool's three stocks to own forever?  If not, what other opportunities await the Foolish investor moving forward?

As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal The Motley Fool's 3 Stocks to Own Forever. These picks are free today! Just click here now to uncover the three companies we love. 

Daniel Jones has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers